Bioengineered Protein Shows Preliminary Promise as New Therapy for Hemophilia

October 25, 2011: Rodney Camire PhD, currently an Associate Professor of Pediatrics and hematology researcher at the Children’s Hospital of Philadelphia, University of Pennsylvania, is a former PhD graduate from our department under the mentorship of Paula Tracy PhD. Rodney lead a study that appears online today (October 25, 2011) in Nature Biotechnology, and will be published in the journal’s November 2011 print issue. “A genetically engineered clotting factor that controlled hemophilia in an animal study offers a novel potential treatment for human hemophilia and a broad range of other bleeding problems. The research team took the naturally occurring coagulation factor Xa and engineered it into a variant that safely controlled bleeding in mouse models of hemophilia.” (http://www.eurekalert.org)